The purpose of this study is to test if visualizing the heart with cardiac MRI/echo will be important in the understanding cardiac function and prediction of cardiopulmonary symptoms, physical effort tolerance, and outcomes in COVID-19 survivors. If successful, the research will allow us to identify the causes of lasting cardiopulmonary symptoms and begin developing cardiac and lung directed therapies accordingly.
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Participants with focal fibrosis based on cardiac imaging (MRI and echocardiogram) > 3 months post-COVID-19 (coronavirus disease 2019) diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post acute COVID-19 infection
Participants with focal fibrosis based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Blood oxygenation of participants at > 3 months post-COVID-19 diagnosis, first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Blood oxygenation of participants at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Lung abnormalities in participants at > 3 months post-COVID-19 infection
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Lung abnormalities in participants at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Quality of life (QOL) in participants at > 3 months post-COVID-19 diagnosis, at first study visit based on clinical indices and symptoms assessed by the (Patient-Reported Outcomes Measurement Information System) PROMIS-29 questionnaire.
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Quality of life (QOL) in participants at 12-36 months post first study visit based on clinical indices and symptoms assessed by the (Patient-Reported Outcomes Measurement Information System) PROMIS-29 questionnaire.
Timeframe: 12-36 months post first study visit
Effort tolerance as measured by a 6-minute walk test at > 3 months post-COVID-19 diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Effort tolerance as measured by a 6-minute walk test at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Participants with edema based on cardiac imaging (MRI and echocardiogram) at > 3 months post-COVID-19 diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Participants with edema based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Participants with diffuse fibrosis based on cardiac imaging (MRI and echocardiogram) at > 3 months post-COVID-19 diagnosis, at first study visit
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Participants with diffuse fibrosis based on cardiac imaging (MRI and echocardiogram) at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit
Quality of life (QOL) in participants at > 3 months post-COVID-19 diagnosis, at first study visit based on clinical indices and symptoms assessed by the Minnesota Living with Heart Failure Questionnaire (MLHFQ)
Timeframe: Day of first study visit, > 3 months post- acute COVID-19 infection
Quality of life (QOL) in participants based on clinical indices and symptoms assessed by the Seattle Angina (SAQ) questionnaire at 12-36 months post first study visit
Timeframe: 12-36 months post first study visit